Menu

ISTOCK, STEINPHOTO

Proposed EPA “Transparency” Rule Criticized

Opponents of the guidelines, which would bar results of many public health studies from use in policy making, include scientific and healthcare organizations.

Jul 18, 2018
Shawna Williams

A proposed rule purportedly aimed at strengthening the transparency of the Environmental Protection Agency’s decision-making process would gut environmental regulations that protect human health, critics argued at a public hearing yesterday at the EPA (July 17). The rule would require that the data underlying any studies used to craft the agency’s policies be publicly available—a bar that would be impossible to reach for many public health studies that rely on confidential health information.

“This would have chilling consequences for the EPA and every person who benefits from clean air and clean water. . . . This proposed rule is an administrative attempt to circumvent the legislative process,” testified US Representative Suzanne Bonamici (D-OR).

See “EPA Seeks to Restrict the Science Used in Policymaking

According to The Atlantic, the guidelines, proposed in April, appear to target regulations that limit particulate air pollution. They are backed by a 1993 study showing that Americans living in cities with higher particulate levels suffered health consequences. That study was the “biggest science fraud that has gone on in this country’s history,” Steven Milloy of the conservative Heartland Institute tells The Atlantic

Other backers of the rule include members of industry trade groups, the Associated Press reports, but critics outnumbered supporters at yesterday’s hearing. The proposal has also drawn opposition from the editors of scientific journals and dozens of public health, medical, academic, and scientific groups.

“If the EPA wanted to engage in a good-faith discussion in how to improve transparency, that’s certainly something they could have done,” Jeremy Berg, the editor-in-chief of Science, tells The Atlantic. “But this doesn’t seem to be that.” 

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.